

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptau153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:59:25 ON 25 SEP 2004

=> file caplus uspatful japio europatful medline biosis embase scisearch
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 15:59:46 ON 25 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:59:46 ON 25 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:59:46 ON 25 SEP 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'EUROPATFULL' ENTERED AT 15:59:46 ON 25 SEP 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 15:59:46 ON 25 SEP 2004

FILE 'BIOSIS' ENTERED AT 15:59:46 ON 25 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 15:59:46 ON 25 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:59:46 ON 25 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

=> s (acryl? or vinyl?) and polymer?
4 FILES SEARCHED...
L1 976875 (ACRYL? OR VINYL?) AND POLYMER?

=> s l1 and (HTB or trifusal)
L2 878 L1 AND (HTB OR TRIFUSAL)

=> s l2 and hydroly?
L3 376 L2 AND HYDROLY?

=> s l3 and covalent
L4 202 L3 AND COVALENT

=> s l3 and copolymer?
<-----User Break----->

L5 129 L3 AND COPOLYMER?
=> s l4 and copolymer?
L6 99 L4 AND COPOLYMER?

=> s l6 and (carboxylic ester)
L7 1 L6 AND (CARBOXYLIC ESTER)

=> d 17 1 ibib abs
'ABS' IS NOT A VALID FORMAT FOR FILE 'EUROPATFULL'

The following are valid formats:

MAX ----- AN, ED, UP, EW, FS, TI, TIDE, TIFR, IN, PA, PAN, AG, AGN,
OS, SO, DT, LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP,
REN, IC (ICM, ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, AB,
ABDE, ABFR, DETD, DETDDE, DETDFR, CLMDE, CLMFR

MAXG ----- MAX plus GI
MAX.OS ----- MAX, OS only
MAXG.OS ---- MAX.OS plus GI
MAX.PS ----- MAX, PS only

IMAX ----- MAX, indented with text labels
IMAX.OS ---- MAX, indented with text labels, OS only
IMAX.PS ---- MAX, indented with text labels, PS only

ALL ----- AN, ED, UP, EW, FS, TI, IN, PA, PAN, AG, AGN, OS, SO, DT,
LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM,
ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, AB*, DETD*, CLM*
(* German or French text if English text is not available)

ALLG ----- ALL plus GI
ALL.OS ---- ALL, OS only
ALLG.OS ---- ALL.OS plus GI
ALL.PS ---- ALL, PS only
IALL ----- ALL, indented with text labels
IALLG ----- IALL plus GI
IALL.OS ---- ALL, indented with text labels, OS only
IALLG.OS --- IALL.OS plus GI
IALL.PS ---- ALL, indented with text labels, PS only

ALLDE ----- AN, ED, UP, EW, FS, TIDE, IN, PA, PAN, AG, AGN, OS, SO, DT,
LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM,
ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, ABDE*, DETDDE*, CLMDE*
(* English or French text if German text is not available)

ALLGDE ----- ALLDE plus GI
ALLDE.OS --- ALLDE, OS only
ALLGDE.OS -- ALLDE.OS plus GI
ALLDE.PS --- ALLDE, PS only

ALLFR ----- AN, ED, UP, EW, FS, TIFR, IN, PA, PAN, AG, AGN, OS, SO, DT,
LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM,
ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, ABFR*, DETDFR*, CLMFR*
(* English or German text if French text is not available)

ALLGFR ----- ALLFR plus GI
ALLFR.OS --- ALLFR, OS only
ALLGFR.OS -- ALLFR.OS plus GI
ALLFR.PS --- ALLFR, PS only

BRIEF ----- AN, ED, UP, EW, FS, TI, IN, PA, PAN, AG, AGN, OS, SO, DT,
LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM,
ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, AB*, MCLM*
(* German or French text if English text is not available)

BRIEFG ----- BRIEF plus GI
BRIEF.OS --- BRIEF, OS only
BRIEFG.OS -- BRIEF.OS plus GI
BRIEF.PS --- BRIEF, PS only
IBRIEF ----- BRIEF, indented with text labels
IBRIEFG ----- IBRIEF plus GI
IBRIEF.OS -- BRIEF, indented with text labels, OS only
IBRIEFG.OS - IBRIEF.OS plus GI
IBRIEF.PS -- BRIEF, indented with text labels, PS only

BIB ----- AN, ED, UP, EW, FS, TI, TIDE, TIFR, IN, PA, PAN, AG, AGN,
OS, SO, DT, LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN
BIB.OS ---- BIB, OS only
BIB.PS ---- BIB, PS only
IBIB ----- BIB, indented with text labels
IBIB.OS ---- BIB, indented with text labels, OS only
IBIB.PS ---- BIB, indented with text labels, PS only
BIBU ----- BIB, with German headers
BIBU.OS ---- BIB, with German headers, OS only
BIBU.PS ---- BIB, with German headers, PS only

STD ----- AN, ED, UP, EW, FS, TI, TIDE, TIFR, IN, PA, SO, DS, PIT, PI,
OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM, ICS), ICA, ICI
STD.OS ---- STD, OS only

STD.PS ----- STD, PS only
 ISTD ----- STD, indented with text labels
 ISTD.OS ---- STD, indented with text labels, OS only
 ISTD.PS ---- STD, indented with text labels, PS only
 STDU ----- STD, with German headers
 STDU.OS ---- STD, with German headers, OS only
 STDU.PS ---- STD, with German headers, PS only

 IND ----- ED, UP, EW, FS, IC (ICM, ICS), ICA, ICI
 IND.OS ---- IND, OS only
 IND.PS ---- IND, PS only

 TRI ----- TI, TIDE, TIFR, IC (ICM, ICS), ICA, ICI, CLMN, PGC, FA, GIS
 TRI.OS ---- TRI, OS only
 TRI.PS ---- TRI, PS only

 TX ----- DETD, CLM
 TX.OS ----- TX, OS only
 TX.PS ----- TX, PS only
 TXDE ----- DETDDE, CLMDE
 TXDE.OS ---- TXDE, OS only
 TXDE.PS ---- TXDE, PS only
 TXFR ----- DETDFR, CLMFR
 TXFR.OS ---- TXFR, OS only
 TXFR.PS ---- TXFR, PS only

To display a particular field or fields, enter the display field codes. For a list of display field codes, enter 'HELP DFIELDS' at an arrow prompt (=>). Examples of formats include: 'TI'; 'AN, TI, AU'; 'BIB, CT'; 'TI, CT'.
 The order of the terms in the formats is not important, but information will be displayed in the same order as the format specification.
 The same formats may be used with the DISPLAY ACC command to display the record for a specified accession number.

ENTER DISPLAY FORMAT (STD):ibib ab

L7 ANSWER 1 OF 1 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1210954 EUROPATFULL EW 200223 FS OS
 TITLE: NEW BIOCOMPATIBLE POLYMER SYSTEMS CARRYING
 TRIFLUSAL OR HTB.
 TRIFLUSAL ODER HTB TRAGENDE BIOKOMPATIBLE
 POLYMERSYSTEME.
 NOUVEAUX SYSTEMES POLYMERES BIOCOMPATIBLES
 PORTEURS DE TRIFLUSAL OU DE HTB.
 INVENTOR(S): GALLARDO RUIZ, Alberto, Paseo de la Castellana, 127,
 E-28046 Madrid, ES;
 RODRIGUEZ CRESPO, Gema, Virgen del Sagrario, 25, E-28027
 Madrid, ES;
 SAN ROMAN DEL BARRIO, Julio, San Lorenzo del Escorial,
 38, E-28290 Las Matas, ES
 PATENT ASSIGNEE(S): J. URIACH & CIA. S.A., Dega Bahi, 59-67, E-08026
 Barcelona, ES
 PATENT ASSIGNEE NO: 1001490
 AGENT: Zumstein, Fritz, Dr. et al., Zumstein & Klingseisen
 Patentanwaelte Braeuhausstrasse 4, 80331 Muenchen, DE
 AGENT NUMBER: 13569
 OTHER SOURCE: BEPA2002048 EP 1210954 A1 0029
 SOURCE: Wila-EPZ-2002-H23-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Spanisch; Veroeffentlichung in Englisch;

DESIGNATED STATES: Verfahren in Englisch
 R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
 PATENT INFO. PUB. TYPE: EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND DATE
EP 1210954	A1 20020605

'OFFENLEGUNGS' DATE: 20020605
 APPLICATION INFO.: EP 2000-956531 20000901
 PRIORITY APPLN. INFO.: ES 1999-2013 19990903
 RELATED DOC. INFO.: WO 00-ES335 000901 INTAKZ
 WO 0117578 010315 INTPNR

ABEN New biocompatible polymeric systems carrying triflusul or HTB are described which result from the polymerization of a monomer A of the acrylic or vinylic type and carrying triflusul or HTB, wherein triflusul or HTB are linked to the remainder of the molecule of said monomer through an in vivo hydrolysable covalent bond, and optionally a second polymerisable monomer B. These new polymeric systems are useful as coating for synthetic biomaterials.

=> d his

(FILE 'HOME' ENTERED AT 15:59:25 ON 25 SEP 2004)

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 15:59:46 ON 25 SEP 2004

L1 976875 S (ACRYL? OR VINYL?) AND POLYMER?
 L2 878 S L1 AND (HTB OR TRIFUSAL)
 L3 376 S L2 AND HYDROLY?
 L4 202 S L3 AND COVALENT
 L5 129 S L3 AND COPOLYMER?
 L6 99 S L4 AND COPOLYMER?
 L7 1 S L6 AND (CARBOXYLIC ESTER)

=> s l6 and ((vascular prosthe?) or valve or stent or graft)
 L8 33 L6 AND ((VASCULAR PROSTHE?) OR VALVE OR STENT OR GRAFT)

=> d 18 1-33 ibib abs

L8 ANSWER 1 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2004:222041 USPATFULL
 TITLE: Antigen PIPA and antibodies that bind thereto
 INVENTOR(S): Mather, Jennie P., Millbrae, CA, UNITED STATES
 Li, Ronghao, Millbrae, CA, UNITED STATES
 Liang, Tony W., San Mateo, CA, UNITED STATES

PATENT INFORMATION:	NUMBER	KIND	DATE
APPLICATION INFO.:	US 2004171814	A1	20040902
	US 2003-713248	A1	20031113 (10)

PRIORITY INFORMATION:	NUMBER	DATE
DOCUMENT TYPE:	US 2002-426192P	20021113 (60)
FILE SEGMENT:	Utility	
LEGAL REPRESENTATIVE:	APPLICATION	
	MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018	

NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 3115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein is disclosure about the identification and characterization of disease and cancer associated antigen PIPA. The invention also provides a family of monoclonal antibodies that bind to antigen PIPA, and methods of diagnosing and treating various human cancers and diseases that express PIPA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2004:145260 USPATFULL
TITLE: CD44-binding ligands
INVENTOR(S): Rondon, Isaac J., San Francisco, CA, UNITED STATES
Edge, Albert, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PATENT ASSIGNEE(S): DYAX CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004110933	A1	20040610
APPLICATION INFO.:	US 2003-663244	A1	20030915 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-410758P	20020913 (60)
	US 2003-469123P	20030509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7240	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides, inter alia, CD44-binding proteins, including CD4-binding antibodies, antibody fragments, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such proteins. Methods of using the proteins to detect CD44 or to modulate a CD44-expressing cell, e.g., in a subject, are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2004:50919 USPATFULL
TITLE: Heteromultimeric TNF ligand family members
INVENTOR(S): Hilbert, David M., Bethesda, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038349	A1	20040226
APPLICATION INFO.:	US 2002-202062	A1	20020725 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-307838P	20010727 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,	

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 14327

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions comprising heteromultimeric complexes, and particularly heterotrimeric complexes, of TNF ligand family members, and methods of using such complexes in the detection, prevention, and treatment of disease. Heteromultimeric TNF ligand polypeptide complexes comprising human TNF ligand polypeptides, including soluble forms of the extracellular domains, as well as membrane bound forms of TNF ligand polypeptides are provided. Heteromultimeric TNF ligand polypeptide complexes are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of heteromultimeric TNF ligand polypeptide complexes. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2004:38077 USPATFULL
TITLE: Dopamine agonist formulations for enhanced central nervous system delivery
INVENTOR(S): Quay, Steven C., Edmonds, WA, UNITED STATES
PATENT ASSIGNEE(S): Nastech Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004028613	A1	20040212
APPLICATION INFO.:	US 2001-891630	A1	20010625 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	8045		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical formulations are described comprising at least one dopamine receptor agonist and one or more mucosal delivery-enhancing agents for enhanced mucosal delivery of the dopamine receptor agonist. In one aspect, the mucosal delivery formulations and methods provide enhanced delivery of the dopamine receptor agonist to the central nervous system (CNS), for example by yielding dopamine receptor agonist concentrations in the cerebral spinal fluid of 5% or greater of the peak dopamine agonist concentrations in the blood plasma following administration to a mammalian subject. Exemplary formulations and methods within the invention utilize apomorphine as the dopamine receptor agonist. Other exemplary methods and formulations focus in intranasal administration of a dopamine receptor agonist. The formulations and methods of the invention are useful for treating a variety of diseases and conditions in mammalian subjects, including Parkinson's disease, male erectile dysfunction, female sexual dysfunction, among others. In alternate aspects, the mucosal delivery formulations and methods of the invention include one, or any combination of, mucosal delivery-enhancing agents selected from (a) aggregation inhibitory agents; (b) charge modifying agents; (c) pH control agents; (d) degradative enzyme inhibitors; (e) mucolytic or

mucus clearing agents; (f) ciliostatic agents; (g) membrane penetration-enhancing agents; (h) modulatory agents of epithelial junction physiology; (i) vasodilator agents; (j) selective transport-enhancing agents; and (k) stabilizing delivery vehicles, carriers, supports or complex-forming agents. These methods and formulations of the invention provide for significantly enhanced absorption of dopamine receptor agonists into or across a nasal mucosal barrier to a target site of action, for example the CNS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:319260 USPATFULL
 TITLE: 28 human secreted proteins
 INVENTOR(S):
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Li, Yi, Sunnyvale, CA, UNITED STATES
 Zeng, ZhiZhen, Lansdale, PA, UNITED STATES
 Kyaw, Hla, Frederick, MD, UNITED STATES
 Fischer, Carrie L., Burke, VA, UNITED STATES
 Li, Haodong, Gaithersburg, MD, UNITED STATES
 Soppet, Daniel R., Centreville, VA, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 Wei, Ying-Fei, Berkeley, CA, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 Young, Paul E., Gaithersburg, MD, UNITED STATES
 Greene, John M., Gaithersburg, MD, UNITED STATES
 Ferrie, Ann M., Painted Post, NY, UNITED STATES
 Hastings, Gregg A., Westlake Village, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

 PATENT INFORMATION: US 2003225009 A1 20031204
 APPLICATION INFO.: US 2002-58993 A1 20020130 (10)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-852659, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. US 2001-852797, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. US 2001-853161, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. WO 1998-US4858, filed on 12 Mar 1998, PENDING

NUMBER	DATE
--------	------

 PRIORITY INFORMATION: US 2001-265583P 20010202 (60)
 US 2001-265583P 20010202 (60)
 US 2001-265583P 20010202 (60)
 US 2001-265583P 20010202 (60)
 US 1997-40762P 19970314 (60)
 US 1997-40710P 19970314 (60)
 US 1997-50934P 19970530 (60)
 US 1997-48100P 19970530 (60)
 US 1997-48357P 19970530 (60)
 US 1997-48189P 19970530 (60)
 US 1997-57765P 19970905 (60)
 US 1997-48970P 19970606 (60)
 US 1997-68368P 19971219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1

LINE COUNT: 29452

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:279119 USPATFULL

TITLE: Monoclonal antibodies to membrane neutrokinin- α

INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, United States

Ebner, Reinhard, Gaithersburg, MD, United States

Ni, Jian, Rockville, MD, United States

Rosen, Craig A., Laytonsville, MD, United States

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

-----	-----	-----
PATENT INFORMATION:	US 6635482	B1 20031021

APPLICATION INFO.:	US 2000-589286	20000608 (9)
--------------------	----------------	--------------

RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000 Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999 Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998 Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996
-----------------------	--

NUMBER	DATE
--------	------

-----	-----
PRIORITY INFORMATION:	US 2000-176015P 20000114 (60)

US 1999-171626P 19991223 (60)

US 1999-171108P 19991216 (60)

US 1999-168624P 19991203 (60)

US 1999-167239P 19991124 (60)

US 1999-145824P 19990727 (60)

US 1999-142659P 19990706 (60)

US 1999-136784P 19990528 (60)

US 1999-131673P 19990429 (60)

US 1999-131278P 19990427 (60)

US 1999-130696P 19990423 (60)

US 1999-130412P 19990416 (60)

US 1999-127598P 19990402 (60)

US 1999-126599P 19990326 (60)

US 1999-124097P 19990312 (60)

US 1999-122388P 19990302 (60)

US 1997-36100P 19970114 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Kemmerer, Elizabeth

ASSISTANT EXAMINER: Bunner, Bridget E.

LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.

NUMBER OF CLAIMS: 32

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 34 Drawing Figure(s); 22 Drawing Page(s)

LINE COUNT: 15413

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel Neutrokinne-alpha, and a splice variant thereof designated Neutrokinne-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokinne-alpha and/or Neutrokinne-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokinne-alpha and/or Neutrokinne-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokinne-alpha and/or Neutrokinne-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:250423 USPATFULL
TITLE: Neutrokinne-alpha and neutrokinne-alpha splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Laird, Michael, Germantown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed on 8 Jun 2000, GRANTED, Pat. No. US 6403770 Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING		

NUMBER DATE

PRIORITY INFORMATION:

US 2001-329508P 20011017 (60)
US 2001-329747P 20011018 (60)
US 2001-330835P 20011031 (60)
US 2001-331478P 20011116 (60)
US 2001-336726P 20011207 (60)
US 2002-368548P 20020401 (60)
US 2000-225628P 20000815 (60)
US 2000-227008P 20000823 (60)
US 2000-234338P 20000922 (60)
US 2000-240806P 20001017 (60)
US 2000-250020P 20001130 (60)
US 2001-276248P 20010316 (60)
US 2001-293499P 20010525 (60)
US 2001-296122P 20010607 (60)
US 2001-304809P 20010713 (60)
US 1999-122388P 19990302 (60)
US 1999-124097P 19990312 (60)
US 1999-126599P 19990326 (60)
US 1999-127598P 19990402 (60)
US 1999-130412P 19990416 (60)
US 1999-130696P 19990423 (60)
US 1999-131278P 19990427 (60)
US 1999-131673P 19990429 (60)
US 1999-136784P 19990528 (60)
US 1999-142659P 19990706 (60)
US 1999-145824P 19990727 (60)
US 1999-167239P 19991124 (60)
US 1999-168624P 19991203 (60)
US 1999-171108P 19991216 (60)
US 1999-171626P 19991223 (60)
US 2000-176015P 20000114 (60)
US 1999-122388P 19990302 (60)
US 1999-124097P 19990312 (60)
US 1999-126599P 19990326 (60)
US 1999-127598P 19990402 (60)
US 1999-130412P 19990416 (60)
US 1999-130696P 19990423 (60)
US 1999-131278P 19990427 (60)
US 1999-131673P 19990429 (60)
US 1999-136784P 19990528 (60)
US 1999-142659P 19990706 (60)
US 1999-145824P 19990727 (60)
US 1999-167239P 19991124 (60)
US 1999-168624P 19991203 (60)
US 1999-171108P 19991216 (60)
US 1999-171626P 19991223 (60)
US 2000-176015P 20000114 (60)
US 1997-36100P 19970114 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

44

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

27 Drawing Page(s)

LINE COUNT:

18884

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to nucleic acid molecules encoding Neutrokinin-alpha and/or Neutrokinin-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokinin-alpha and/or Neutrokinin-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind

Neutrokin-alpha and/or Neutrokin-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2003:246895 USPATFULL
TITLE: Uses of VEGF-E
INVENTOR(S): Ferrara, Napoleone, San Francisco, CA, United States
Kuo, Sophia S., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6620784	B1	20030916
APPLICATION INFO.:	US 2000-723749		20001127 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-265686, filed on 10 Mar 1999, now patented, Pat. No. US 6455283 Continuation-in-part of Ser. No. US 1998-184216, filed on 2 Nov 1998, now abandoned Continuation-in-part of Ser. No. US 1998-40220, filed on 17 Mar 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Saoud, Christine J.		
LEGAL REPRESENTATIVE:	Cui, Steven X.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	4371		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2003:243796 USPATFULL
TITLE: Interleukin-1 homolog zilla7
INVENTOR(S): Sheppard, Paul O., Granite Falls, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170205	A1	20030911
APPLICATION INFO.:	US 2002-132113	A1	20020424 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-286481P	20010425 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gary E. Parker, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	

LINE COUNT: 2432

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Homologs of interleukin-1, materials and methods for making them, compositions comprising them, and methods of using them are disclosed. The homologs are proteins comprising a sequence of amino acid residues as shown in SEQ ID NO:2 from residue 32 through residue 166. The proteins have inflammation modulating activity and are useful within related research and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:187916 USPATFULL

TITLE: Fhm, a novel member of the TNF ligand supergene family
INVENTOR(S): Hsu, Hailing, Moorpark, CA, UNITED STATES
Wooden, Scott Kenneth, Thousand Oaks, CA, UNITED STATES
Boyle, William James, Moorpark, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003129706 A1 20030710

APPLICATION INFO.: US 2002-286696 A1 20021101 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-632287, filed on 3 Aug 2000, PENDING

NUMBER DATE

PRIORITY INFORMATION: US 1999-147294P 19990804 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357

NUMBER OF CLAIMS: 71

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 5069

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:166014 USPATFULL

TITLE: Polypeptides homologous to VEGF and BMP1

INVENTOR(S): Ferrara, Napoleone, San Francisco, CA, UNITED STATES
Kuo, Sophia S., San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2003113870 A1 20030619

APPLICATION INFO.: US 2002-178442 A1 20020619 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-265686, filed on 10 Mar 1999, GRANTED, Pat. No. US 6455283 Continuation-in-part of Ser. No. US 1998-184216, filed on 2 Nov 1998, ABANDONED Continuation-in-part of Ser. No. US 1998-40220, filed on 17 Mar 1998, GRANTED, Pat. No. US 6391311

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA,
94080
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 4273

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2003:129800 USPATFULL
TITLE: Diagnostic methods using antibodies to Neutrokinne-alpha
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6562579	B1	20030513
APPLICATION INFO.:	US 2000-588947		20000608 (9)
RELATED APPLN. INFO.:			Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000 Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999 Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998 Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-36100P	19970114 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Byler, Yvonne
ASSISTANT EXAMINER: Prasad, Sarada C
LEGAL REPRESENTATIVE: Human Genome Sciences, Inc
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 33 Drawing Figure(s); 22 Drawing Page(s)

LINE COUNT: 15469

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel Neutrokinine-alpha, and a splice variant thereof designated Neutrokinine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokinine-alpha and/or Neutrokinine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokinine-alpha and/or Neutrokinine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokinine-alpha and/or Neutrokinine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:120997 USPATFULL

TITLE: 25 human prostate and prostate cancer associated proteins

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003083481 A1 20030501

APPLICATION INFO.: US 2002-36542 A1 20020107 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2000-US19666, filed on 20 Jul 2000, UNKNOWN

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1999-144972P 19990721 (60)

US 1999-148681P 19990813 (60)

US 1999-149173P 19990817 (60)

US 1999-158004P 19991006 (60)

US 2000-194689P 20000405 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

LINE COUNT: 26241

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified prostate or prostate cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "prostate antigens" or alternatively "prostate cancer antigens", and the use of such prostate or prostate cancer antigens for detecting disorders of the prostate, particularly the presence of prostate cancer and prostate cancer metastases. This invention relates to prostate or prostate cancer antigens as well as vectors, host cells, antibodies directed to prostate or prostate cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders of the prostate, particularly prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of prostate or prostate

cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:86317 USPATFULL

TITLE: Polynucleotide encoding a novel human potassium channel alpha-subunit, K+alphaM1, and variants thereof

INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana M., North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra, Wallingford, CT, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059923	A1	20030327
APPLICATION INFO.:	US 2001-999220	A1	20011101 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245383P	20001102 (60)
	US 2000-257780P	20001221 (60)
	US 2001-269854P	20010220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	30 Drawing Page(s)	
LINE COUNT:	16037	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding K+alphaM1 polypeptides, fragments and homologues thereof. The invention also provides novel polynucleotides encoding the K+alphaM1 variant polypeptides, K+alphaM1.v1 and K+alphaM1.v2, in addition to fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+alphaM1, K+alphaM1.v1, and K+alphaM1.v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:49537 USPATFULL

TITLE: Applications of light-emitting nanoparticles

INVENTOR(S): Korgel, Brian A., Round Rock, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003034486	A1	20030220
APPLICATION INFO.:	US 2002-109608	A1	20020328 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2001-302594P 20010702 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ERIC B. MEYERTONS, CONLEY, ROSE & TAYON, P.C., P.O BOX 398, AUSTIN, TX, 78767-0398
NUMBER OF CLAIMS: 598
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Page(s)
LINE COUNT: 4628

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the production of a robust, chemically stable, crystalline, passivated nanoparticle and composition containing the same, that emit light with high efficiencies and size-tunable and excitation energy tunable color. The methods include the thermal degradation of a precursor molecule in the presence of a capping agent at high temperature and elevated pressure. A particular composition prepared by the methods is a passivated silicon nanoparticle composition displaying discrete optical transitions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2003:47644 USPATFULL
TITLE: Fhm, a novel member of the TNF ligand supergene family
INVENTOR(S): Hsu, Hailing, Moorpark, CA, United States
Wooden, Scott Kenneth, Thousand Oaks, CA, United States
Boyle, William James, Moorpark, CA, United States
PATENT ASSIGNEE(S): Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6521422	B1	20030218
APPLICATION INFO.:	US 2000-632287		20000803 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147294P	19990804 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Eyler, Yvonne	
ASSISTANT EXAMINER:	Andres, Janet L.	
LEGAL REPRESENTATIVE:	Marshall, Gerstein & Borun	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	4749	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2003:30870 USPATFULL
TITLE: Angiogenesis-modulating compositions and uses
INVENTOR(S): Ling, Leona E., Winchester, MA, UNITED STATES
Sanicola-Nadel, Michele, Winchester, MA, UNITED STATES

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION: US 2003022819 A1 20030130
APPLICATION INFO.: US 2001-883848 A1 20010618 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-211919P 20000616 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624

NUMBER OF CLAIMS: 34

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 8945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hedgehog agonists and antagonists can be used to regulate angiogenesis, and have utility in treating tissue repair and cancer, and to prevent angiogenesis driven pathologies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:3266 USPATFULL

TITLE: Light-emitting nanoparticles and method of making same

INVENTOR(S): Korgel, Brian A., Round Rock, TX, UNITED STATES

Johnston, Keith P., Austin, TX, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003003300 A1 20030102

APPLICATION INFO.: US 2002-109578 A1 20020328 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-302594P 20010702 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ERIC B. MEYERTONS, CONLEY, ROSE & TAYON, P.C., P.O. BOX 398, AUSTIN, TX, 78767-0398

NUMBER OF CLAIMS: 598

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 31 Drawing Page(s)

LINE COUNT: 4619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the production of a robust, chemically stable, crystalline, passivated nanoparticle and composition containing the same, that emit light with high efficiencies and size-tunable and excitation energy tunable color. The methods include the thermal degradation of a precursor molecule in the presence of a capping agent at high temperature and elevated pressure. A particular composition prepared by the methods is a passivated silicon nanoparticle composition displaying discrete optical transitions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2002:246563 USPATFULL

TITLE: Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)

INVENTOR(S): Ferrara, Napoleone, San Francisco, CA, United States

Kuo, Sophia S., San Francisco, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6455283	B1	20020924
APPLICATION INFO.:	US 1999-265686		19990310 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-184216, filed on 2 Nov 1998, now abandoned Continuation-in-part of Ser. No. US 1998-40220, filed on 17 Mar 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Spector, Lorraine		
LEGAL REPRESENTATIVE:	Cui, Steven X.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	4363		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2002:235521 USPATFULL
 TITLE: Process for ex vivo formation of mammalian bone and uses thereof
 INVENTOR(S): Kale, Sujata, Boston, MA, UNITED STATES
 Long, Michael W., Northville, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127711	A1	20020912
APPLICATION INFO.:	US 2000-753043	A1	20001227 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Steven L. Highlander, Fulbright & Jaworski L.L.P.,, 600 Congress Avenue Suite 2400, Austin, TX, 78701		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		
LINE COUNT:	3032		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2002:213736 USPATFULL
 TITLE: Neutrokinin-alpha and Neutrokinin-alpha splice variant
 INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES

PATENT ASSIGNEE(S) :

Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ulrich, Stephen, Rockville, MD, UNITED STATES
Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

PATENT INFORMATION:

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002115112	A1	20020822
APPLICATION INFO.:	US 2001-929493	A1	20010815 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, PENDING		
	Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING		
	Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING		
	Continuation-in-part of Ser. No. US 2000-589287, filed on 8 Jun 2000, PENDING		
	Continuation-in-part of Ser. No. US 2000-586288, filed on 2 Jun 2000, PATENTED		
	Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING		
	Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING		
	Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING		

PRIORITY INFORMATION:

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225628P	20000815 (60)
	US 2000-227008P	20000823 (60)
	US 2000-234338P	20000922 (60)
	US 2000-240806P	20001017 (60)
	US 2000-250020P	20001130 (60)
	US 2001-276248P	20010316 (60)
	US 2001-293499P	20010525 (60)
	US 2001-296122P	20010607 (60)
	US 2001-304809P	20010713 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850**NUMBER OF CLAIMS:**

117

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

22 Drawing Page(s)

LINE COUNT:

18178

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to nucleic acid molecules encoding Neutrokinin-alpha and/or Neutrokinin-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokinin-alpha and/or Neutrokinin-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention

further relates to antibodies or portions thereof that specifically bind Neutrokinne-alpha and/or Neutrokinne-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2002:137146 USPATFULL
TITLE: Antibodies to neutrokinne-alpha
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403770	B1	20020611
APPLICATION INFO.:	US 2000-589287		20000608 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000 Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999 Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998 Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-176015P	20000114 (60)
	US 1999-171626P	19991223 (60)
	US 1999-171108P	19991216 (60)
	US 1999-168624P	19991203 (60)
	US 1999-167239P	19991124 (60)
	US 1999-145824P	19990727 (60)
	US 1999-142659P	19990706 (60)
	US 1999-136784P	19990528 (60)
	US 1999-131673P	19990429 (60)
	US 1999-131278P	19990427 (60)
	US 1999-130696P	19990423 (60)
	US 1999-130412P	19990416 (60)
	US 1999-127598P	19990402 (60)
	US 1999-126599P	19990326 (60)
	US 1999-124097P	19990312 (60)
	US 1999-122388P	19990302 (60)
	US 1997-36100P	19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary L.
ASSISTANT EXAMINER: Prasad, Sarada C
LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.
NUMBER OF CLAIMS: 292
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 15430
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel Neutrokinne-alpha, and a splice variant thereof designated Neutrokinne-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokinne-alpha and/or Neutrokinne-alphaSV polypeptides, including

soluble forms of the extracellular domain. Neutrokinin-alpha and/or Neutrokinin-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokinin-alpha and/or Neutrokinin-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2002:98856 USPATFULL
TITLE: Pharmaceuticals and apparatus providing diagnosis and selective tissue necrosis
INVENTOR(S): Mills, Randell L., Cochranville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002051751	A1	20020502
APPLICATION INFO.:	US 2001-819141	A1	20010327 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-454012, filed on 30 May 1995, GRANTED, Pat. No. US 6224848 Continuation of Ser. No. US 1992-950973, filed on 23 Sep 1992, ABANDONED Continuation of Ser. No. US 1987-55591, filed on 28 May 1987, ABANDONED Continuation-in-part of Ser. No. US 1986-849046, filed on 7 Apr 1986, GRANTED, Pat. No. US 4815448 Continuation-in-part of Ser. No. US 1985-713448, filed on 19 Mar 1985, GRANTED, Pat. No. US 4815447		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	70		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Page(s)		
LINE COUNT:	3411		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceuticals and Apparatus used in combination for diagnosis and tissue necrosis applicable to provide effective and selective therapy using the Mossbauer absorption phenomenon. Selected pharmaceutical compounds containing a radiation absorber isotope are administered to a tissue and excited by a radiation source which provides energy at the corresponding resonant Mossbauer absorption frequency of isotope containing pharmaceutical, where excitation effects nuclear transitions to cause highly selective energy absorption in the selected target tissue. For diagnostic purposes, de-excitation fluorescence of the isotope is monitored. For therapeutic purposes, the energy is converted to particle radiation by the isotope at the target tissue by internal conversion followed by an Auger electron cascade which results in radiolysis of DNA resulting in lethal double strand breaks in the DNA molecules of the target tissue. The tissue selectivity is achieved by providing a Mossbauer absorption frequency of the target tissue which differs from that of surrounding tissue. The difference in frequency is due to the properties of the pharmaceutical, and/or an imposition of external magnetic fields or narrow beam ultrasonic power at the site of the target tissue. The magnitude of radiation absorption at the resonant Mossbauer frequency for the target tissue is of the order of one million times the absorption of surrounding nontarget tissue, which has a different Mossbauer absorption frequency, thereby producing considerably reduced side effects in comparison to conventional chemotherapy or radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2002:92245 USPATFULL
TITLE: Human genome-derived single exon nucleic acid probes useful for gene expression analysis
INVENTOR(S): Penn, Sharron Gaynor, San Mateo, CA, UNITED STATES
Rank, David Russell, Fremont, CA, UNITED STATES
Chen, Wensheng, Mountain View, CA, UNITED STATES
Hanzel, David Kagen, Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002048763	A1	20020425
APPLICATION INFO.:	US 2001-864761	A1	20010523 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-774203, filed on 29 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-632366, filed on 3 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-608408, filed on 30 Jun 2000, PENDING Continuation-in-part of Ser. No. WO 2001-US666, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US667, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US664, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US669, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US665, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US668, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US663, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US662, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US661, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US670, filed on 30 Jan 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-242636	20001004
	US 2000-180312P	20000204 (60)
	US 2000-207456P	20000526 (60)
	US 2000-234687P	20000921 (60)
	US 2000-236359P	20000927 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 9057

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and apparatus for predicting, confirming and displaying functional regions from genomic sequence data are used to identify 16,834 unique human genome-derived single exon probes useful for gene expression analysis, particularly gene expression analysis by microarray. Also presented are genome-derived single exon microarrays that include such probes, peptides encoded by the exons, and antibodies thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2002:12261 USPATFULL
TITLE: Uteroglobin-like polynucleotides, polypeptides, and

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002006640	A1	20020117
APPLICATION INFO.:	US 2001-846258	A1	20010502 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US30326, filed on 3 Nov 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-163395P	19991104 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	12076	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human uteroglobin-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human uteroglobin-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human uteroglobin-like polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2001:63226 USPATFULL
TITLE: Pharmaceuticals providing diagnosis and selective tissue necrosis using Mossbauer absorber atom
INVENTOR(S): Mills, Randell L., R.D. 2, Cochranville, PA, United States 19330

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6224848	B1	20010501
APPLICATION INFO.:	US 1995-454012		19950530 (8)
RELATED APPLN. INFO.:			Continuation of Ser. No. US 1992-950973, filed on 23 Sep 1992, now abandoned Continuation of Ser. No. US 1987-55591, filed on 28 May 1987, now abandoned Continuation-in-part of Ser. No. US 1986-849046, filed on 7 Apr 1986, now patented, Pat. No. US 4815448 Continuation-in-part of Ser. No. US 1985-713448, filed on 19 Mar 1985, now patented, Pat. No. US 4815447

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dudash, Diana
ASSISTANT EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Giulio A., Triano, III, Nicholas P.

NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 3073

CAS INDEXING IS AVAILABLE FOR THIS PATENT

AB Pharmaceuticals and Apparatus used in combination for diagnosis and tissue necrosis applicable to provide effective and selective therapy using the Mossbauer absorption phenomenon. Selected pharmaceutical

compounds containing a radiation absorber isotope are administered to a tissue and excited by a radiation source which provides energy at the corresponding resonant Mossbauer absorption frequency of isotope containing pharmaceutical, where excitation effects nuclear transitions to cause highly selective energy absorption in the selected target tissue. For diagnostic purposes, de-excitation fluorescence of the isotope is monitored. For therapeutic purposes, the energy is converted to particle radiation by the isotope at the target tissue by internal conversion followed by an Auger electron cascade which results in radiolysis of DNA resulting in lethal double strand breaks in the DNA molecules of the target tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 33 USPATFULL on STN

ACCESSION NUMBER: 1999:106108 USPATFULL
TITLE: Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
INVENTOR(S): Lee, John C., San Antonio, TX, United States
Yeh, Lee-Chuan C., San Antonio, TX, United States
PATENT ASSIGNEE(S): Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5948428		19990907
APPLICATION INFO.:	US 1996-761468		19961206 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-570752, filed on 12 Dec 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Fish & Neave, Haley, James F., Ruskin, Barbara A.		
NUMBER OF CLAIMS:	78		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	3767		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a method for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. Methods of treating tissue degenerative conditions in a mammal using the pharmaceutical compositions are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 33 USPATFULL on STN

ACCESSION NUMBER: 1998:72592 USPATFULL
TITLE: Sensory and motor neuron derived factor (SMDF)
INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osherson, Phyllis L., Woodside, CA, United States

PATENT ASSIGNEE(S) : Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5770567		19980623
APPLICATION INFO.:	US 1994-339517		19941114 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula K.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	3771		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic methods of preparing SMDF are disclosed. SMDF contains a β -type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 33 USPATFULL on STN
ACCESSION NUMBER: 1998:65003 USPATFULL
TITLE: Sensory and motor neuron derived factor (SMDF)
INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osherooff, Phyllis L., Woodside, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5763213		19980609
APPLICATION INFO.:	US 1995-428298		19950425 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-339517, filed on 14 Nov 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula K.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	3837		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic methods of preparing SMDF are disclosed. SMDF contains a β -type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 33 USPATFULL on STN
ACCESSION NUMBER: 1998:57880 USPATFULL
TITLE: Methods involving sensory and motor neuron derived factor (SMDF)
INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osheroft, Phyllis L., Woodside, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5756456		19980526
APPLICATION INFO.:	US 1995-428927		19950425 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-339517, filed on 14 Nov 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Mutzell, Paula R.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	3757		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for activating the HER2 receptor comprising contacting a cell which expresses this receptor with SMDF polypeptides is discussed. A method for enhancing differentiation and/or proliferation of a cell using SMDF polypeptides is also disclosed. These methods may be performed in vitro or in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 33 USPATFULL on STN
ACCESSION NUMBER: 97:83613 USPATFULL
TITLE: Antibodies to SMDF
INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osheroft, Phyllis L., Woodside, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5667780		19970916
APPLICATION INFO.:	US 1995-428926		19950425 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-339517, filed on 14 Nov 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Johnson, Nancy A.		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	3743		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated SMDF, isolated DNA encoding SMDF, and antibodies to SMDF are disclosed. SMDF contains a β -type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine

phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 33 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1210954 EUROPATFULL EW 200223 FS OS
TITLE: NEW BIOCOMPATIBLE POLYMER SYSTEMS CARRYING
TRIFLUSAL OR HTB.
TRIFLUSAL ODER HTB TRAGENDE BIOKOMPATIBLE
POLYMERSYSTEME.
NOUVEAUX SYSTEMES POLYMERES BIOCOMPATIBLES
PORTEURS DE TRIFLUSAL OU DE HTB.
INVENTOR(S): GALLARDO RUIZ, Alberto, Paseo de la Castellana, 127,
E-28046 Madrid, ES;
RODRIGUEZ CRESPO, Gema, Virgen del Sagrario, 25, E-28027
Madrid, ES;
SAN ROMAN DEL BARRIO, Julio, San Lorenzo del Escorial,
38, E-28290 Las Matas, ES
PATENT ASSIGNEE(S): J. URIACH & CIA. S.A., Dega Bahi, 59-67, E-08026
Barcelona, ES
PATENT ASSIGNEE NO: 1001490
AGENT: Zumstein, Fritz, Dr. et al., Zumstein & Klingseisen
Patentanwaelte Braeuhausstrasse 4, 80331 Muenchen, DE
13569
AGENT NUMBER:
OTHER SOURCE: BEPA2002048 EP 1210954 A1 0029
SOURCE: Wila-EPZ-2002-H23-T1b
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Spanisch; Veroeffentlichung in Englisch;
Verfahren in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R
GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R
SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale
Anmeldung)
PATENT INFORMATION:

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 1210954	A1 20020605 20020605
APPLICATION INFO.:	EP 2000-956531	20000901
PRIORITY APPLN. INFO.:	ES 1999-2013	19990903
RELATED DOC. INFO.:	WO 00-ES335 WO 0117578	000901 INTAKZ 010315 INTPNR

L8 ANSWER 33 OF 33 EUROPATFULL COPYRIGHT 2004 WILA on STN

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 871471 EUROPATFULL EW 200426 FS PS
TITLE: COMPOSITIONS USING MORPHOGENIC PROTEINS AND STIMULATORY
FACTORS.
ZUSAMMENSETZUNGEN UNTER VERWENDUNG VON MORPHOGENEN
PROTEINEN UND STIMULATIONSFAKTOREN.
COMPOSITIONS THERAPEUTIQUES METTANT EN OEUVRE DES
PROTEINES MORPHOGENIQUES ET DES FACTEURS DE STIMULATION.
INVENTOR(S): LEE, John, C., 1119 Haltown Drive, San Antonio, TX

PATENT ASSIGNEE(S) : 78213, US;
YEH, Lee-Chuan, C., 8027 Indian Bend, San Antonio, TX
78250, US

PATENT ASSIGNEE NO: STRYKER CORPORATION, 2725 Fairfield Road, Kalamazoo, MI
49001, US

AGENT: 558084

AGENT NUMBER: VOSSIUS & PARTNER, Siebertstrasse 4, 81675 Muenchen, DE
100314

OTHER SOURCE: MEPB2004027 EP 0871471 B1 0060

SOURCE: Wila-EPS-2004-H26-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R
GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO. PUB. TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale
Anmeldung)

PATENT INFORMATION:

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 871471	B1 20040623 19981021
APPLICATION INFO.:	EP 1996-944806	19961211
PRIORITY APPLN. INFO.:	US 1995-570752	19951212
RELATED DOC. INFO.:	WO 96-US19876	961211 INTAKZ
	WO 1997021447	970619 INTPNR
REFERENCE PAT. INFO.:	EP 436469 A	EP 514720 A
	WO 92-09697 A	WO 92-21365 A
	WO 93-05823 A	US 5324819 A
REF. NON-PATENT-LIT.:	DATABASE WPI Section Ch, Week 9717 Derwent Publications Ltd., London, GB; Class B04, AN 97-188310 XP002030695 & JP09048738 A (SNOW BRAND MILK PROD CO LTD), 18 February 1997	